These mechanisms are highly conserved across multiple cancer types, including ICC, GC, HCC, NSCLC, CRC, MM, PC, OSCC, LUSC, and NPC, highlighting the potential of METTL5 as a diagnostic biomarker and therapeutic target. This evidence concerns the gene METTL5 and hepatocellular carcinoma.